Cargando…

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54

AIMS: In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15–16% in stable patients with a prior myocardial infarction (MI) 1–3 years earlier. We report the efficacy and safety in the subpopulation recommended for treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dellborg, Mikael, Bonaca, Marc P, Storey, Robert F, Steg, P Gabriel, Im, Kyung A, Cohen, Marc, Bhatt, Deepak L, Oude Ophuis, Ton, Budaj, Andrezej, Hamm, Christian, Spinar, Jindrich, Kiss, Robert G, Lopez-Sendon, José, Kamensky, Gabriel, Van de Werf, Frans, Ardissino, Diego, Kontny, Frederic, Montalescot, Gilles, Johanson, Per, Bengtsson, Olof, Himmelmann, Anders, Braunwald, Eugene, Sabatine, Marc S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749839/ https://www.ncbi.nlm.nih.gov/pubmed/31218354 http://dx.doi.org/10.1093/ehjcvp/pvz020

Ejemplares similares

Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018)

Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial
por: Furtado, Remo H. M., et al.
Publicado: (2020)

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction
por: Magnani, Giulia, et al.
Publicado: (2021)

Gut Microbiota‐Dependent Trimethylamine N‐oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS‐TIMI 54 Trial
por: Gencer, Baris, et al.
Publicado: (2020)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Implications of the PEGASUS-TIMI 54 trial for US clinical practice
por: Bradley, Steven M, et al.
Publicado: (2017)

Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P‐TIMI 50 trial
por: Freedman, Benjamin L., et al.
Publicado: (2022)

Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50
por: Berg, David D., et al.
Publicado: (2021)

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
por: Bergmark, Brian A., et al.
Publicado: (2018)

Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P‐TIMI 50 trial
por: Freedman, Benjamin L., et al.
Publicado: (2023)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Clinical benefit of long-term use of dual antiplatelet therapy for acute myocardial infarction patients with the PEGASUS-TIMI 54 criteria
por: Lee, Kwan Yong, et al.
Publicado: (2022)

Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients
por: Åstrand, Magnus, et al.
Publicado: (2018)

Dynamic TIMI Risk Score for STEMI
por: Amin, Sameer T., et al.
Publicado: (2013)

The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial
por: Husted, Steen, et al.
Publicado: (2014)

Despite the Virus, the Special Issue for the 16th Pegasus Student Conference
por: Marcuccio, Salvo, et al.
Publicado: (2020)

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
por: Murphy, Sabina A., et al.
Publicado: (2008)

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50
por: Kidd, Stephen K., et al.
Publicado: (2016)

Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
por: Bhatt, Deepak L., et al.
Publicado: (2019)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes
por: Røysland, Ragnhild, et al.
Publicado: (2012)

Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a “real world” STEMI population: results from the Italian “CARDIO-STEMI SANREMO” registry
por: Sanchez, Federico, et al.
Publicado: (2021)

Commissioning of the UCLA PEGASUS Photoinjector Laboratory
por: Telfer, S, et al.
Publicado: (2001)

Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes
por: Husted, Steen, et al.
Publicado: (2016)

Plasma Omega‐3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN‐TIMI 36
por: Zelniker, Thomas A., et al.
Publicado: (2021)

International Perspectives on the Impact of the COVID-19 Pandemic on Adherence to Prescribed Dual Antiplatelet Therapy: A Window Into Acute Cardiovascular Care
por: Pollack, Charles V., et al.
Publicado: (2022)

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial
por: Lindholm, Daniel, et al.
Publicado: (2014)

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial
por: Zelniker, Thomas A., et al.
Publicado: (2021)

Efficacy and Safety of Vorapaxar by Intensity of Background Lipid‐Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P‐TIMI 50 Trial
por: Gilchrist, Ian C., et al.
Publicado: (2021)

Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51
por: Gibson, William J., et al.
Publicado: (2019)

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
por: Andell, Pontus, et al.
Publicado: (2015)

GRACE Score among Six Risk Scoring Systems (CADILLAC, PAMI, TIMI, Dynamic TIMI, Zwolle) Demonstrated the Best Predictive Value for Prediction of Long-Term Mortality in Patients with ST-Elevation Myocardial Infarction
por: Littnerova, Simona, et al.
Publicado: (2015)

Predictors of Nonuse of a High‐Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib‐Thrombolysis in Myocardial Infarction 52 (SOLID‐TIMI 52) Trial
por: Eisen, Alon, et al.
Publicado: (2017)

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
por: James, Stefan, et al.
Publicado: (2010)

Proposal for a IR Waveguide SASE FEL at the PEGASUS Injector
por: Reiche, S, et al.
Publicado: (2001)

Embedding Algorithms for Quantum Annealers with Chimera and Pegasus Connection Topologies
por: Zbinden, Stefanie, et al.
Publicado: (2020)

The PEGASUS Conferences: A unique avenue to bridge evidence and action
por: Amri, Michelle, et al.
Publicado: (2020)

Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial
por: Gao, Chao, et al.
Publicado: (2020)

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins
por: Singh, Awadhesh K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ahh0mf3o07blpdvrhj1ok3q5ag